
Fig. 1



A = Eprex
B = PER.C6-α2,6ST-EPO
C = PER.C6-EPO

Fig. 2

A.




Fig. 2

PER.C6-EPO-022 (Suspension, VPRO)

B.





Fig. 3




1 = PER.C6-EPO in VPRO
2 = PER.C6-EPO + α2,6 ST in VPRO
3 = EPREX

Fig. 4

A.


PER.C6-EPO



* Number of sialic acids per glycan

B.

PER.C6-ST-EPO



* Number of sialic acids per glycan

Fig. 5



1 2
3 4
Fractionation using chromatography
12
11
10
9
8
8
7
6
5
4
3
2
1
sialic acid content
1 = PER.C6-EPO
2 = PER.C6-ST-EPO
3 = Fractionated PER.C6-ST-EPO
4 = Eprex®

Fig. 6



100
90
80
70
60
50
40
30
20
10
0
1200
1600
2120
2620
3040
3600
2641.222
2632.233
2587.27
2543.16
0011.7

Fig. 7




avg. sialic acid content:
3.0
9.0
12.6
12.4
1
2
3
4
EPO isoforms
(number of sialic acids per EPO molecule)
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0

Fig. 8

A.


Amp
CMV
ColE1
BGH p(A)
pCP-EPO
7334 bp
f1 ori
BGH p(A)
SV40
EPO
Neo
CMV
SV40 p(A)

B.



Amp
CMV
ColE1
ST3 GALIV
pEPO-ST3
8306 bp
BGH p(A)
BGH p(A)
EPO
f1 ori
SV40
CMV
SV40 p(A)
Neo

Fig. 9




Fig. 10




Fig. 11



2541.44
4514.7
100
90
80
70
60
50
40
30
20
10
0
% Intensity
2176.27
2544.31
2582.45
2184.30
0
1200
1660
2120
2580
3040
3500
Mass (m/z)

Fig. 12

